These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19262559)

  • 1. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice.
    Hou JM; Zhao X; Tian L; Li G; Zhang R; Yao B; Deng HX; Yang JL; Wei YQ
    Acta Pharmacol Sin; 2009 Mar; 30(3):355-63. PubMed ID: 19262559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
    Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
    Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.
    Mashino K; Sadanaga N; Tanaka F; Ohta M; Yamaguchi H; Mori M
    Mol Cancer Ther; 2002 Aug; 1(10):785-94. PubMed ID: 12492111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.
    Felizardo TC; Wang JC; McGray RA; Evelegh C; Spaner DE; Fowler DH; Bramson JL; Medin JA
    Gene Ther; 2011 Oct; 18(10):986-95. PubMed ID: 21490686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.
    Hillinger S; Yang SC; Zhu L; Huang M; Duckett R; Atianzar K; Batra RK; Strieter RM; Dubinett SM; Sharma S
    J Immunol; 2003 Dec; 171(12):6457-65. PubMed ID: 14662845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
    Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J
    J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells.
    He XZ; Wang L; Zhang YY
    World J Gastroenterol; 2008 Jan; 14(4):532-40. PubMed ID: 18203284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
    Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice.
    Liu GY; Jia QY; Li ZJ; Li YG; Zhang MM; Liu MY; Wang XL; Li Y
    Immunobiology; 2014 Jun; 219(6):475-81. PubMed ID: 24657179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
    Furumoto K; Soares L; Engleman EG; Merad M
    J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
    Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
    J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.